12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

Amsterdam Molecular, uniQure deal

Amsterdam Molecular's board unanimously recommended dissolving the company's assets into newco uniQure in a stock deal. Amsterdam said it is facing a "precarious" financial position with cash expected to last until April and the deal is "the only viable way to secure a capital injection." Amsterdam shareholders will receive one new uniQure depository receipt (DR) for every outstanding Amsterdam Molecular share. Amsterdam Molecular will delist. The uniQure DRs will not be listed.

Amsterdam said uniQure will continue to...

Read the full 371 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >